Taketo Kawai

Prof. Taketo Kawai


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
JMJimpei Miyakawa
Jimpei Miyakawa
TKTaketo Kawai
Taketo Kawai
KMKatsuhiro Makino
Katsuhiro Makino
YAYoshiyuki Akiyama
Yoshiyuki Akiyama
YYYuta Yamada
Yuta Yamada
HKHaruki Kume
Haruki Kume

22 September 2023 in International Journal of Urology
Verified
Journal Article
Closed access
STSatoru Taguchi
Satoru Taguchi
TKTaketo Kawai
Taketo Kawai
YAYoshiki Ambe
Yoshiki Ambe
KKKenjiro Kishitani
Kenjiro Kishitani
KSKazuma Sugimoto
Kazuma Sugimoto
HKHaruki Kume
Haruki Kume

2 August 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
STSatoru Taguchi
Satoru Taguchi
TKTaketo Kawai
Taketo Kawai
TNTohru Nakagawa
Tohru Nakagawa
YNYu Nakamura
Yu Nakamura
JKJun Kamei
Jun Kamei
HKHaruki Kume
Haruki Kume
Although the albumin-to-globulin ratio (AGR) is a promising biomarker, no study has investigated its prognostic significance for advanced urothelial carcinoma (UC). This study conformed to the REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria. We retrospectively reviewed 176 patients with advanced UC treated with pembrolizumab between 2018 and 2020. We evaluated the associations between pretreatment clinicopathological variables, including the AGR and performance status (PS), with progression-free survival, cancer-specific survival, and overall survival. The Cox proportional hazards model was used for univariate and multivariable analyses. The AGR was dichotomized as < 0.95 and ≥ 0.95 based on receiver operating characteristic curve analysis. After excluding 26 cases with missing data from the total of 176 cases, 109 (73%) patients experienced disease progression, 75 (50%) died from UC, and 6 (4%) died of other causes (median survival = 12 months). Multivariate analyses identified PS ≥ 2 and pretreatment AGR < 0.95 as independent poor prognostic factors for all endpoints. Furthermore, a prognostic risk model incorporating these two variables achieved a relatively high concordance index for all endpoints. This is the first report to evaluate the significance of AGR in advanced UC. Pretreatment AGR < 0.95 may serve as a prognostic marker for advanced UC treated with pembrolizumab.

1 July 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
TKTaketo Kawai
Taketo Kawai
YSYusuke Sato
Yusuke Sato
KMKatsuhiro Makino
Katsuhiro Makino
YYYuta Yamada
Yuta Yamada
ANAkira Nomiya
Akira Nomiya
HKHaruki Kume
Haruki Kume

17 June 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TKTaketo Kawai
Taketo Kawai
MOMizuki Onozawa
Mizuki Onozawa
STSatoru Taguchi
Satoru Taguchi
Masaki ShiotaMasaki Shiota
Masaki Shiota
SSShinichi Sakamoto
Shinichi Sakamoto
J(Japan Study Group of Prostate Cancer (J-CaP)
Japan Study Group of Prostate Cancer (J-CaP)
Background: In previous large-scale studies conducted through 2010, androgen deprivation therapy (ADT) was the most common initial treatment for prostate cancer patients in Japan. However, recent advancements in treatment technologies have significantly affected the management of prostate cancer in Japan. This study analyzed the trends in initial treatments for prostate cancer based on two nationwide surveys. Methods: Two Japan-wide multi-institutional surveys, J-CaP2010 and J-CaP2016, were conducted to enroll patients newly histologically diagnosed with prostate cancer in 2010 and 2016–18, respectively. Both surveys included age at diagnosis, initial PSA level, ISUP Grade Group, TNM classification, and initial treatment for prostate cancer. Results: J-CaP2010 included data from 8192 patients across 140 institutions, whereas J-CaP2016 included data from 21 841 patients across 186 institutions. In J-CaP2016, the proportion of radical prostatectomy (RP) and radiation therapy (RT) in the initial treatment increased (from 32% to 36% and 21% to 26%, respectively), whereas the proportion of ADT decreased (from 40% to 29%) compared with those in J-CaP2010. The increase in RP or RT was noticeable in patients aged 75 years and older (from 20% to 38%) and those with high-risk localized cancer (from 58% to 74%) or locally advanced cancer (from 38% to 56%). The proportion of active surveillance or watchful waiting increased in patients with low-risk localized cancer (from 21% to 41%). The proportion of robot-assisted RP within all RPs and the proportion of intensity-modulated RT within all RTs increased remarkably (from 2.3% to 78% and 20% to 50%, respectively). Conclusions: In Japan, RP and RT have increased as initial treatments for prostate cancer, whereas ADT has decreased. Consequently, RP has emerged as the most commonly selected initial treatment, replacing ADT.

22 August 2022 in International Journal of Urology
Verified
Journal Article
Open access
STSatoru Taguchi
Satoru Taguchi
TKTaketo Kawai
Taketo Kawai
TNTohru Nakagawa
Tohru Nakagawa
JMJimpei Miyakawa
Jimpei Miyakawa
KKKenjiro Kishitani
Kenjiro Kishitani
HKHaruki Kume
Haruki Kume
Objectives: Although the treatment strategy for advanced urothelial carcinoma (aUC) has drastically changed since pembrolizumab was introduced in 2017, studies revealing current survival rates in aUC are lacking. This study aimed to assess (1) the improvement in survival among real‐world patients with aUC after the introduction of pembrolizumab and (2) the direct survival‐prolonging effect of pembrolizumab.Methods: This multicenter retrospective study included 531 patients with aUC undergoing salvage chemotherapy, including 200 patients treated in the pre‐pembrolizumab era (2003–2011; earlier era) and 331 patients treated in a recent 5‐year period (2016–2020; recent era). Using propensity score matching (PSM), cancer‐specific survival (CSS) and overall survival (OS) were compared between the earlier and recent eras, in addition to between the recent era, both with and without pembrolizumab use, and the earlier era.Results: After PSM, the recent era cohort had significantly longer CSS (21 months) and OS (19 months) than the earlier era cohort (CSS and OS: 12 months). In secondary analyses using PSM, patients treated with pembrolizumab had significantly longer CSS (25 months) and OS (24 months) than those in the earlier era cohort (CSS and OS: 11 months), whereas patients who did not receive pembrolizumab in the recent era had similar outcomes (CSS and OS: 14 months) as the earlier era cohort (CSS and OS: 12 months).Conclusions: Patients with aUC treated in the recent era exhibited significantly longer survival than those treated before the introduction of pembrolizumab. The improved survival was primarily attributable to the use of pembrolizumab.